Acarbose
The therapeutic efficacy of Acarbose can be decreased when used in combination with Metolazone.
Acebutolol
Metolazone may increase the hypotensive activities of Acebutolol.
Aceclofenac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Aceclofenac.
Advertisement
Acemetacin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Acemetacin.
Acetohexamide
The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Metolazone.
Acetyl salicylate
The therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid.
Advertisement
Acetyldigitoxin
The risk or severity of adverse effects can be increased when Metolazone is combined with Acetyldigitoxin.
Aclidinium
The serum concentration of Metolazone can be increased when it is combined with Aclidinium.
Adapalene
The therapeutic efficacy of Metolazone can be decreased when used in combination with Adapalene.
Advertisement
Albuterol
Salbutamol may increase the hypokalemic activities of Metolazone.
Alclometasone
Alclometasone may increase the hypokalemic activities of Metolazone.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.
Aldosterone
Aldosterone may increase the hypokalemic activities of Metolazone.
Alfacalcidol
The risk or severity of hyperkalemia can be increased when Alfacalcidol is combined with Metolazone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Metolazone.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Metolazone.
Aliskiren
Metolazone may increase the hypotensive activities of Aliskiren.
Allopurinol
The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Metolazone.
Alminoprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Alminoprofen.
Alogliptin
The therapeutic efficacy of Alogliptin can be decreased when used in combination with Metolazone.
Alphaprodine
The risk or severity of adverse effects can be increased when Alphaprodine is combined with Metolazone.
Alprenolol
Metolazone may increase the hypotensive activities of Alprenolol.
Ambrisentan
Metolazone may increase the hypotensive activities of Ambrisentan.
Amcinonide
Amcinonide may increase the hypokalemic activities of Metolazone.
Amifostine
Metolazone may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Metolazone may increase the hypotensive activities of Amifostine.
Amiloride
The risk or severity of adverse effects can be increased when Metolazone is combined with Amiloride.
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Metolazone.
Amlodipine
Amlodipine may increase the hypotensive activities of Metolazone.
Amobarbital
Amobarbital may increase the orthostatic hypotensive activities of Metolazone.
Amphetamine
Amphetamine may increase the hypotensive activities of Metolazone.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Metolazone.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Metolazone.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Metolazone is combined with Amyl Nitrite.
Androstenedione
Androstenedione may increase the hypokalemic activities of Metolazone.
Antipyrine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Antipyrine.
Apazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Metolazone.
Apraclonidine
The risk or severity of adverse effects can be increased when Metolazone is combined with Apraclonidine.
Apremilast
The therapeutic efficacy of Metolazone can be decreased when used in combination with Apremilast.
Arbutamine
Arbutamine may increase the hypokalemic activities of Metolazone.
Arformoterol
Arformoterol may increase the hypokalemic activities of Metolazone.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Metolazone.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Metolazone.
Aspirin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Acetylsalicylic acid.
Atenolol
Atenolol may increase the hypotensive activities of Metolazone.
Atracurium
The serum concentration of Metolazone can be increased when it is combined with Atracurium.
Atracurium Besylate
The serum concentration of Metolazone can be increased when it is combined with Atracurium besylate.
Atropine
The serum concentration of Metolazone can be increased when it is combined with Atropine.
Avanafil
Avanafil may increase the antihypertensive activities of Metolazone.
Azelastine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Azelastine.
Azilsartan
The risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Metolazone is combined with Azilsartan medoxomil.
Balsalazide
The therapeutic efficacy of Metolazone can be decreased when used in combination with Balsalazide.
Bambuterol
Bambuterol may increase the hypokalemic activities of Metolazone.
Barbexaclone
Barbexaclone may increase the orthostatic hypotensive activities of Metolazone.
Barbital
Barbital may increase the orthostatic hypotensive activities of Metolazone.
Beclomethasone Dipropionate
Beclomethasone dipropionate may increase the hypokalemic activities of Metolazone.
Benactyzine
The serum concentration of Metolazone can be increased when it is combined with Benactyzine.
Benazepril
The risk or severity of hypotension can be increased when Metolazone is combined with Benazepril.
Bendroflumethiazide
Bendroflumethiazide may increase the hypotensive activities of Metolazone.
Benztropine
The serum concentration of Metolazone can be increased when it is combined with Benzatropine.
Benzydamine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Benzydamine.
Bepridil
Metolazone may increase the hypotensive activities of Bepridil.
Betamethasone
Betamethasone may increase the hypokalemic activities of Metolazone.
Betaxolol
Betaxolol may increase the hypotensive activities of Metolazone.
Bethanidine
Bethanidine may increase the hypotensive activities of Metolazone.
Bimatoprost
Metolazone may increase the hypotensive activities of Bimatoprost.
Biperiden
The serum concentration of Metolazone can be increased when it is combined with Biperiden.
Bisoprolol
Metolazone may increase the hypotensive activities of Bisoprolol.
Bitolterol
Bitolterol may increase the hypokalemic activities of Metolazone.
Bitolterol Mesylate
Bitolterol may increase the hypokalemic activities of Metolazone.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Metolazone.
Bosentan
Bosentan may increase the hypotensive activities of Metolazone.
Bosentan Anhydrous
Bosentan may increase the hypotensive activities of Metolazone.
Bretylium
Metolazone may increase the hypotensive activities of Bretylium.
Brimonidine
Brimonidine may increase the antihypertensive activities of Metolazone.
Bromfenac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Bromfenac.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Metolazone.
Budesonide
Budesonide may increase the hypokalemic activities of Metolazone.
Bufexamac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Bufexamac.
Bumetanide
The risk or severity of adverse effects can be increased when Metolazone is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Metolazone.
Bupranolol
Metolazone may increase the hypotensive activities of Bupranolol.
Buprenorphine
The risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Metolazone.
Butylscopolamine
The serum concentration of Metolazone can be increased when it is combined with Butylscopolamine.
Cafedrine
Metolazone may increase the hypotensive activities of Cafedrine.
Calcifediol
The risk or severity of hyperkalemia can be increased when Calcidiol is combined with Metolazone.
Calcifediol Anhydrous
The risk or severity of hyperkalemia can be increased when Calcidiol is combined with Metolazone.
Calcipotriene
The risk or severity of hyperkalemia can be increased when Calcipotriol is combined with Metolazone.
Calcitriol
The risk or severity of hyperkalemia can be increased when Calcitriol is combined with Metolazone.
Calcium Acetate
Metolazone may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.
Calcium Carbonate
Metolazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.
CALCIUM CARBONATE, PRECIPITATED
Metolazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.
Calcium Chloride
Metolazone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.
Calcium Chloride Anhydrous
Metolazone may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.
Calcium Citrate
Metolazone may decrease the excretion rate of Calcium Citrate which could result in a higher serum level.
Calcium Glubionate
Metolazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.
Calcium gluceptate
Metolazone may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.
Calcium Gluconate
Metolazone may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.
Calcium Lactate
Metolazone may decrease the excretion rate of Calcium lactate which could result in a higher serum level.
CALCIUM LEVULINATE
Metolazone may decrease the excretion rate of Calcium levulinate which could result in a higher serum level.
Canagliflozin
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.
Canagliflozin Anhydrous
The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.
Candesartan
Metolazone may increase the hypotensive activities of Candesartan.
Candesartan Cilexetil
The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Metolazone.
Captopril
The risk or severity of hypotension can be increased when Metolazone is combined with Captopril.
Carbamazepine
The risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine.
Carprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Carprofen.
Carteolol
Carteolol may increase the hypotensive activities of Metolazone.
Carvedilol
Metolazone may increase the hypotensive activities of Carvedilol.
Casein Allergenic Extract
Metolazone may decrease the excretion rate of Casein which could result in a higher serum level.
Celecoxib
The therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib.
Celiprolol
Celiprolol may increase the hypokalemic activities of Metolazone.
Chloroquine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Chloroquine.
Chlorothiazide
Metolazone may increase the hypotensive activities of Chlorothiazide.
Chlorphenoxamine
The serum concentration of Metolazone can be increased when it is combined with Chlorphenoxamine.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metolazone.
Chlorpropamide
The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Metolazone.
Chlorthalidone
Chlorthalidone may increase the hypotensive activities of Metolazone.
Cholecalciferol
The risk or severity of hyperkalemia can be increased when Cholecalciferol is combined with Metolazone.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The therapeutic efficacy of Metolazone can be decreased when used in combination with Choline magnesium trisalicylate.
Ciclesonide
Ciclesonide may increase the hypokalemic activities of Metolazone.
Cicletanine
Metolazone may increase the hypotensive activities of Cicletanine.
Cilazapril
The risk or severity of hypotension can be increased when Metolazone is combined with Cilazapril.
Citalopram
Citalopram may increase the hyponatremic activities of Metolazone.
Clenbuterol
Clenbuterol may increase the hypokalemic activities of Metolazone.
Clevidipine
The risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.
Clobetasol
Clobetasol may increase the hypokalemic activities of Metolazone.
Clobetasol Propionate
Clobetasol propionate may increase the hypokalemic activities of Metolazone.
Clobetasone
Clobetasone may increase the hypokalemic activities of Metolazone.
Clocortolone
Clocortolone may increase the hypokalemic activities of Metolazone.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Metolazone.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Metolazone.
Clonidine
Clonidine may increase the hypotensive activities of Metolazone.
Clonixin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Clonixin.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Metolazone.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Metolazone.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Metolazone.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Metolazone.
Colesevelam
Colesevelam can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Metolazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Metolazone.
Cortisone Acetate
Cortisone acetate may increase the hypokalemic activities of Metolazone.
Cryptenamine
Metolazone may increase the hypotensive activities of Cryptenamine.
Curcumin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Curcumin.
Cyclopenthiazide
Metolazone may increase the hypotensive activities of Cyclopenthiazide.
Cyclopentolate
The serum concentration of Metolazone can be increased when it is combined with Cyclopentolate.
Cyclophosphamide
The risk or severity of severe leukopenia can be increased when Metolazone is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The risk or severity of severe leukopenia can be increased when Metolazone is combined with Cyclophosphamide.
Cyclothiazide
Metolazone may increase the hypotensive activities of Cyclothiazide.
Dapagliflozin
The risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin.
Darifenacin
The serum concentration of Metolazone can be increased when it is combined with Darifenacin.
Debrisoquin
Debrisoquin may increase the hypotensive activities of Metolazone.
Deflazacort
Deflazacort may increase the hypokalemic activities of Metolazone.
Deserpidine
Metolazone may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Metolazone.
Deslanoside
The risk or severity of adverse effects can be increased when Metolazone is combined with Deslanoside.
Desloratadine
The serum concentration of Metolazone can be increased when it is combined with Desloratadine.
Desonide
Desonide may increase the hypokalemic activities of Metolazone.
Desoximetasone
Desoximetasone may increase the hypokalemic activities of Metolazone.
Desoxycorticosterone acetate
Desoxycorticosterone acetate may increase the hypokalemic activities of Metolazone.
Desoxycorticosterone Pivalate
Desoxycorticosterone Pivalate may increase the hypokalemic activities of Metolazone.
Desvenlafaxine
Desvenlafaxine may increase the hyponatremic activities of Metolazone.
Dexamethasone
Dexamethasone may increase the hypokalemic activities of Metolazone.
Dexetimide
The serum concentration of Metolazone can be increased when it is combined with Dexetimide.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metolazone.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Metolazone is combined with Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Dextromoramide is combined with Metolazone.
Dezocine
The risk or severity of adverse effects can be increased when Dezocine is combined with Metolazone.
Diazoxide
The risk or severity of adverse effects can be increased when Metolazone is combined with Diazoxide.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Metolazone is combined with Diclofenamide.
Diclofenac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Diclofenac.
Dicyclomine
The serum concentration of Metolazone can be increased when it is combined with Dicyclomine.
Diflorasone
Diflorasone may increase the hypokalemic activities of Metolazone.
Diflucortolone
Difluocortolone may increase the hypokalemic activities of Metolazone.
Diflunisal
The therapeutic efficacy of Metolazone can be decreased when used in combination with Diflunisal.
Difluprednate
Difluprednate may increase the hypokalemic activities of Metolazone.
Digitoxin
The risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin.
Digoxin
The risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin.
Dihydralazine
Dihydralazine may increase the hypotensive activities of Metolazone.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metolazone.
Dihydrotachysterol
The risk or severity of hyperkalemia can be increased when Dihydrotachysterol is combined with Metolazone.
Diltiazem
Diltiazem may increase the hypotensive activities of Metolazone.
Dinutuximab
The risk or severity of adverse effects can be increased when Metolazone is combined with Dinutuximab.
Diphenhydramine
The serum concentration of Metolazone can be increased when it is combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metolazone.
Dipivefrin
Dipivefrin may increase the hypokalemic activities of Metolazone.
Dipyridamole
The risk or severity of adverse effects can be increased when Metolazone is combined with Dipyridamole.
Dipyrone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole.
Dobutamine
Dobutamine may increase the hypokalemic activities of Metolazone.
Dofetilide
Metolazone may increase the QTc-prolonging activities of Dofetilide.
Dorzolamide
Metolazone may increase the hypotensive activities of Dorzolamide.
Doxazosin
Doxazosin may increase the hypotensive activities of Metolazone.
Doxercalciferol
The risk or severity of hyperkalemia can be increased when Doxercalciferol is combined with Metolazone.
Droxicam
The therapeutic efficacy of Metolazone can be decreased when used in combination with Droxicam.
Droxidopa
Droxidopa may increase the hypokalemic activities of Metolazone.
Dulaglutide
The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Metolazone.
Duloxetine
Metolazone may increase the orthostatic hypotensive activities of Duloxetine.
Empagliflozin
The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Metolazone.
Enalapril
The risk or severity of hypotension can be increased when Metolazone is combined with Enalapril.
Enalaprilat
The risk or severity of hypotension can be increased when Metolazone is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of hypotension can be increased when Metolazone is combined with Enalaprilat.
Epinephrine
Epinephrine may increase the hypokalemic activities of Metolazone.
Eplerenone
The risk or severity of adverse effects can be increased when Metolazone is combined with Eplerenone.
Epoprostenol
Metolazone may increase the hypotensive activities of Epoprostenol.
Eprosartan
Metolazone may increase the hypotensive activities of Eprosartan.
Ergocalciferol
The risk or severity of hyperkalemia can be increased when Ergocalciferol is combined with Metolazone.
Escitalopram
Escitalopram may increase the hyponatremic activities of Metolazone.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Metolazone.
Estrone
Estrone may increase the hypokalemic activities of Metolazone.
Etanercept
The therapeutic efficacy of Metolazone can be decreased when used in combination with Etanercept.
Ethacrynate
The risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.
Ethanol
Ethanol may increase the orthostatic hypotensive activities of Metolazone.
Ethylmorphine
The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metolazone.
Etodolac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Etodolac.
Etofenamate
The therapeutic efficacy of Metolazone can be decreased when used in combination with Etofenamate.
Etoricoxib
The therapeutic efficacy of Metolazone can be decreased when used in combination with Etoricoxib.
Evening primrose oil
The therapeutic efficacy of Metolazone can be decreased when used in combination with Evening primrose oil.
Exenatide
The therapeutic efficacy of Exenatide can be decreased when used in combination with Metolazone.
Felbinac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Felbinac.
Felodipine
Metolazone may increase the hypotensive activities of Felodipine.
Fenbufen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Fenbufen.
Fenoldopam
Metolazone may increase the hypotensive activities of Fenoldopam.
Fenoprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Fenoprofen.
Fenoterol
Fenoterol may increase the hypokalemic activities of Metolazone.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Metolazone.
Ferulic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Ferulic acid.
Fesoterodine
The serum concentration of Metolazone can be increased when it is combined with Fesoterodine.
Flavoxate
The serum concentration of Metolazone can be increased when it is combined with Flavoxate.
Flavoxate Hydrochloride
The serum concentration of Metolazone can be increased when it is combined with Flavoxate.
Floctafenine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Floctafenine.
Fludrocortisone
Fludrocortisone may increase the hypokalemic activities of Metolazone.
Flumethasone
Flumethasone may increase the hypokalemic activities of Metolazone.
Flunisolide
Flunisolide may increase the hypokalemic activities of Metolazone.
Flunisolide Anhydrous (obsolete)
Flunisolide may increase the hypokalemic activities of Metolazone.
Fluocinolone Acetonide
Fluocinolone Acetonide may increase the hypokalemic activities of Metolazone.
Fluocinonide
Fluocinonide may increase the hypokalemic activities of Metolazone.
Fluocortolone
Fluocortolone may increase the hypokalemic activities of Metolazone.
Fluorometholone
Fluorometholone may increase the hypokalemic activities of Metolazone.
Fluoxetine
Fluoxetine may increase the hyponatremic activities of Metolazone.
FLUPREDNIDENE
Fluprednidene may increase the hypokalemic activities of Metolazone.
Fluprednisolone
Fluprednisolone may increase the hypokalemic activities of Metolazone.
Flurandrenolide
Flurandrenolide may increase the hypokalemic activities of Metolazone.
Flurbiprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Flurbiprofen.
Fluticasone
Fluticasone may increase the hypokalemic activities of Metolazone.
Fluticasone Furoate
Fluticasone furoate may increase the hypokalemic activities of Metolazone.
Fluticasone propionate
Fluticasone propionate may increase the hypokalemic activities of Metolazone.
Fluvoxamine
Fluvoxamine may increase the hyponatremic activities of Metolazone.
Formestane
Formestane may increase the hypokalemic activities of Metolazone.
Formoterol
Formoterol may increase the hypokalemic activities of Metolazone.
Fosinopril
The risk or severity of hypotension can be increased when Metolazone is combined with Fosinopril.
Fostamatinib
Fostamatinib may increase the antihypertensive activities of Metolazone.
Furazolidone
Furazolidone may increase the hypotensive activities of Metolazone.
Furosemide
The risk or severity of adverse effects can be increased when Metolazone is combined with Furosemide.
Gallamine Triethiodide
The serum concentration of Metolazone can be increased when it is combined with Gallamine Triethiodide.
Glibornuride
The therapeutic efficacy of Glibornuride can be decreased when used in combination with Metolazone.
Gliclazide
The therapeutic efficacy of Gliclazide can be decreased when used in combination with Metolazone.
Glimepiride
The therapeutic efficacy of Glimepiride can be decreased when used in combination with Metolazone.
Glipizide
The therapeutic efficacy of Glipizide can be decreased when used in combination with Metolazone.
Gliquidone
The therapeutic efficacy of Gliquidone can be decreased when used in combination with Metolazone.
Glyburide
The therapeutic efficacy of Glyburide can be decreased when used in combination with Metolazone.
Glycopyrronium
The serum concentration of Metolazone can be increased when it is combined with Glycopyrronium.
Guanabenz
Metolazone may increase the hypotensive activities of Guanabenz.
Guanadrel
Guanadrel may increase the hypotensive activities of Metolazone.
Guanethidine
Metolazone may increase the hypotensive activities of Guanethidine.
Guanfacine
Guanfacine may increase the hypotensive activities of Metolazone.
Halcinonide
Halcinonide may increase the hypokalemic activities of Metolazone.
Halobetasol
Ulobetasol may increase the hypokalemic activities of Metolazone.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Metolazone.
Heroin
The risk or severity of adverse effects can be increased when Heroin is combined with Metolazone.
Hexobarbital
Hexobarbital may increase the orthostatic hypotensive activities of Metolazone.
Hexoprenaline
Hexoprenaline may increase the hypokalemic activities of Metolazone.
Homatropine
The serum concentration of Metolazone can be increased when it is combined with Homatropine.
Hydralazine
Hydralazine may increase the hypotensive activities of Metolazone.
Hydrochlorothiazide
Metolazone may increase the hypotensive activities of Hydrochlorothiazide.
Hydrocodone
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Metolazone.
Hydrocortisone
Hydrocortisone may increase the hypokalemic activities of Metolazone.
Hydroflumethiazide
Metolazone may increase the hypotensive activities of Hydroflumethiazide.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Metolazone.
Hyoscyamine
The serum concentration of Metolazone can be increased when it is combined with Hyoscyamine.
Ibuprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Ibuprofen.
Icatibant
The therapeutic efficacy of Metolazone can be decreased when used in combination with Icatibant.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Metolazone.
Imidapril
The risk or severity of hypotension can be increased when Metolazone is combined with Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Metolazone.
Indacaterol
Indacaterol may increase the hypokalemic activities of Metolazone.
Indapamide
Metolazone may increase the hypotensive activities of Indapamide.
Indobufen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Indobufen.
Indomethacin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Indomethacin.
Indoramin
Indoramin may increase the hypotensive activities of Metolazone.
Insulin Detemir
The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Metolazone.
Insulin Glargine
The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Metolazone.
insulin human, rDNA origin
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Metolazone.
Insulin Lispro
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.
Insulin, Aspart Protamine, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone.
Insulin, Aspart, Human
The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Metolazone.
Insulin, Glulisine, Human
The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Metolazone.
Insulin, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone.
Insulin, Protamine Lispro, Human
The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Metolazone.
Insulin, Regular, Pork
The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Metolazone.
Ipratropium
The serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.
Ipratropium cation
The serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.
Iproniazid
Iproniazid may increase the hypotensive activities of Metolazone.
Irbesartan
Metolazone may increase the hypotensive activities of Irbesartan.
Isocarboxazid
Isocarboxazid may increase the hypotensive activities of Metolazone.
Isoetharine
Isoetarine may increase the hypokalemic activities of Metolazone.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Metolazone.
Isoproterenol
Isoprenaline may increase the hypokalemic activities of Metolazone.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Metolazone is combined with Isoxsuprine.
Isradipine
Isradipine may increase the hypotensive activities of Metolazone.
Ivabradine
Metolazone may increase the arrhythmogenic activities of Ivabradine.
Kebuzone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Kebuzone.
Ketanserin
Ketanserin may increase the hypotensive activities of Metolazone.
Ketoprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketoprofen.
Ketorolac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac.
Labetalol
Metolazone may increase the hypotensive activities of Labetalol.
Lacidipine
Metolazone may increase the hypotensive activities of Lacidipine.
Latanoprost
Metolazone may increase the hypotensive activities of Latanoprost.
Leflunomide
The therapeutic efficacy of Metolazone can be decreased when used in combination with Leflunomide.
Lercanidipine
Metolazone may increase the hypotensive activities of Lercanidipine.
Levalbuterol
Levosalbutamol may increase the hypokalemic activities of Metolazone.
Levobunolol
The risk or severity of adverse effects can be increased when Metolazone is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metolazone.
Levodopa
Metolazone may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metolazone.
Levomilnacipran
Levomilnacipran may increase the hyponatremic activities of Metolazone.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Metolazone.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Metolazone.
Licorice Allergenic Extract
Licorice may increase the hypokalemic activities of Metolazone.
Limonene, (+)-
The therapeutic efficacy of Metolazone can be decreased when used in combination with (4R)-limonene.
Linagliptin
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Metolazone.
Liraglutide
The therapeutic efficacy of Liraglutide can be decreased when used in combination with Metolazone.
Lisinopril
The risk or severity of hypotension can be increased when Metolazone is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of hypotension can be increased when Metolazone is combined with Lisinopril.
Lithium
Metolazone may decrease the excretion rate of Lithium which could result in a higher serum level.
Lithium Cation
Metolazone may decrease the excretion rate of Lithium which could result in a higher serum level.
Lofexidine
Metolazone may increase the hypotensive activities of Lofexidine.
Lornoxicam
The therapeutic efficacy of Metolazone can be decreased when used in combination with Lornoxicam.
Losartan
Metolazone may increase the hypotensive activities of Losartan.
Loteprednol
Loteprednol may increase the hypokalemic activities of Metolazone.
Loxoprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Loxoprofen.
Macitentan
Metolazone may increase the hypotensive activities of Macitentan.
Magnesium Salicylate
The therapeutic efficacy of Metolazone can be decreased when used in combination with Magnesium salicylate.
Manidipine
Metolazone may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Metolazone is combined with Mannitol.
Masoprocol
The therapeutic efficacy of Metolazone can be decreased when used in combination with Masoprocol.
Mecamylamine
The risk or severity of adverse effects can be increased when Metolazone is combined with Mecamylamine.
Meclofenamate
The therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.
Meclofenamic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Meclofenamic acid.
Medrysone
Medrysone may increase the hypokalemic activities of Metolazone.
Mefenamic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Mefenamic acid.
Meloxicam
The therapeutic efficacy of Metolazone can be decreased when used in combination with Meloxicam.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Metolazone.
Mephobarbital
Methylphenobarbital may increase the orthostatic hypotensive activities of Metolazone.
Mepirodipine
Metolazone may increase the antihypertensive activities of Barnidipine.
Mesalamine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.
Metaproterenol
Orciprenaline may increase the hypokalemic activities of Metolazone.
Metformin
The therapeutic efficacy of Metformin can be decreased when used in combination with Metolazone.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Metolazone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metolazone.
Methantheline
The serum concentration of Metolazone can be increased when it is combined with Methantheline.
Methazolamide
The risk or severity of adverse effects can be increased when Metolazone is combined with Methazolamide.
Methixene
The serum concentration of Metolazone can be increased when it is combined with Metixene.
Methohexital
Methohexital may increase the orthostatic hypotensive activities of Metolazone.
Methscopolamine
The serum concentration of Metolazone can be increased when it is combined with Methscopolamine.
Methscopolamine Bromide
The serum concentration of Metolazone can be increased when it is combined with Methylscopolamine bromide.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metolazone.
Methyldopa
Metolazone may increase the hypotensive activities of Methyldopa.
METHYLDOPA ANHYDROUS
Metolazone may increase the hypotensive activities of Methyldopa.
Methylene blue
Methylene blue may increase the hypotensive activities of Metolazone.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Metolazone.
Methylprednisolone
Methylprednisolone may increase the hypokalemic activities of Metolazone.
Metipranolol
Metolazone may increase the hypotensive activities of Metipranolol.
Metoprolol
Metoprolol may increase the hypotensive activities of Metolazone.
Metyrosine
Metolazone may increase the hypotensive activities of Metyrosine.
Mibefradil
Metolazone may increase the hypotensive activities of Mibefradil.
Miglitol
The therapeutic efficacy of Miglitol can be decreased when used in combination with Metolazone.
Miglustat
The therapeutic efficacy of Miglustat can be decreased when used in combination with Metolazone.
Milnacipran
Milnacipran may increase the hyponatremic activities of Metolazone.
Minaprine
Minaprine may increase the hypotensive activities of Metolazone.
Minoxidil
Minoxidil may increase the hypotensive activities of Metolazone.
Moclobemide
Moclobemide may increase the hypotensive activities of Metolazone.
Moexipril
The risk or severity of hypotension can be increased when Metolazone is combined with Moexipril.
Molsidomine
Molsidomine may increase the hypotensive activities of Metolazone.
Mometasone
Mometasone may increase the hypokalemic activities of Metolazone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.
Moxonidine
Moxonidine may increase the hypotensive activities of Metolazone.
MYCOPHENOLATE
The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.
Mycophenolate Mofetil
The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Metolazone.
Nabumetone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Nabumetone.
Nadolol
Metolazone may increase the hypotensive activities of Nadolol.
Naftifine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Naftifine.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Metolazone.
Naproxen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Naproxen.
Nateglinide
The therapeutic efficacy of Nateglinide can be decreased when used in combination with Metolazone.
Nebivolol
Metolazone may increase the hypotensive activities of Nebivolol.
Nefazodone
Nefazodone may increase the hyponatremic activities of Metolazone.
Nepafenac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Nepafenac.
Nesiritide
The risk or severity of adverse effects can be increased when Metolazone is combined with Nesiritide.
Nialamide
Nialamide may increase the hypotensive activities of Metolazone.
Nicardipine
Metolazone may increase the hypotensive activities of Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Metolazone.
Nifedipine
The risk or severity of adverse effects can be increased when Metolazone is combined with Nifedipine.
Niflumic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic Acid.
Nilvadipine
Metolazone may increase the hypotensive activities of Nilvadipine.
Nimesulide
The therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.
Nimodipine
Nimodipine may increase the hypotensive activities of Metolazone.
Nisoldipine
Nisoldipine may increase the hypotensive activities of Metolazone.
Nitrendipine
Metolazone may increase the hypotensive activities of Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metolazone.
Nitroglycerin
The risk or severity of adverse effects can be increased when Metolazone is combined with Nitroglycerin.
Nitroprusside
Nitroprusside may increase the hypotensive activities of Metolazone.
Norepinephrine
Norepinephrine may increase the hypokalemic activities of Metolazone.
Normethadone
The risk or severity of adverse effects can be increased when Normethadone is combined with Metolazone.
Obinutuzumab
Metolazone may increase the hypotensive activities of Obinutuzumab.
Octotropine Methylbromide
The serum concentration of Metolazone can be increased when it is combined with Anisotropine Methylbromide.
Octylonium
The serum concentration of Metolazone can be increased when it is combined with Otilonium.
Oenothera biennis seed extract
The therapeutic efficacy of Metolazone can be decreased when used in combination with Evening primrose oil.
Olmesartan
Olmesartan may increase the hypotensive activities of Metolazone.
Olodaterol
Olodaterol may increase the hypokalemic activities of Metolazone.
Olopatadine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.
Olsalazine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.
Opium
The risk or severity of adverse effects can be increased when Opium is combined with Metolazone.
Orphenadrine
The serum concentration of Metolazone can be increased when it is combined with Orphenadrine.
Ouabain
The risk or severity of adverse effects can be increased when Metolazone is combined with Ouabain.
Ovine Digoxin Immune Fab
The risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin Immune Fab (Ovine).
Oxaprozin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.
Oxcarbazepine
The risk or severity of hyponatremia can be increased when Metolazone is combined with Oxcarbazepine.
Oxitropium
The serum concentration of Metolazone can be increased when it is combined with Oxitropium.
Oxprenolol
Metolazone may increase the hypotensive activities of Oxprenolol.
Oxybutynin
The serum concentration of Metolazone can be increased when it is combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Metolazone.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Metolazone.
Oxyphenbutazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxyphenbutazone.
Oxyphenonium
The serum concentration of Metolazone can be increased when it is combined with Oxyphenonium.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Metolazone.
Palmidrol
The therapeutic efficacy of Metolazone can be decreased when used in combination with Palmidrol.
Pancuronium
The serum concentration of Metolazone can be increased when it is combined with Pancuronium.
Pancuronium Bromide
The serum concentration of Metolazone can be increased when it is combined with Pancuronium.
Papaverine
The risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.
Paramethasone
Paramethasone may increase the hypokalemic activities of Metolazone.
Parecoxib
The therapeutic efficacy of Metolazone can be decreased when used in combination with Parecoxib.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Metolazone.
Pargyline
Pargyline may increase the hypotensive activities of Metolazone.
Paricalcitol
The risk or severity of hyperkalemia can be increased when Paricalcitol is combined with Metolazone.
Paroxetine
Paroxetine may increase the hyponatremic activities of Metolazone.
Parthenolide
The therapeutic efficacy of Metolazone can be decreased when used in combination with Parthenolide.
Penbutolol
Metolazone may increase the hypotensive activities of Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Metolazone.
Pentobarbital
Pentobarbital may increase the orthostatic hypotensive activities of Metolazone.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Metolazone.
Perindopril
The risk or severity of hypotension can be increased when Metolazone is combined with Perindopril.
Phenelzine
Phenelzine may increase the hypotensive activities of Metolazone.
Phenformin
The therapeutic efficacy of Phenformin can be decreased when used in combination with Metolazone.
Phenobarbital
Phenobarbital may increase the orthostatic hypotensive activities of Metolazone.
Phenoxybenzamine
Metolazone may increase the hypotensive activities of Phenoxybenzamine.
Phentolamine
Metolazone may increase the hypotensive activities of Phentolamine.
Phentolamine Mesylate
Metolazone may increase the hypotensive activities of Phentolamine.
Phenylbutazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Phenylbutazone.
Phenylpropanolamine
Phenylpropanolamine may increase the hypokalemic activities of Metolazone.
Pimecrolimus
The therapeutic efficacy of Metolazone can be decreased when used in combination with Pimecrolimus.
Pinacidil
Pinacidil may increase the hypotensive activities of Metolazone.
Pindolol
Metolazone may increase the hypotensive activities of Pindolol.
Pioglitazone
The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Metolazone.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Metolazone.
Pipecuronium
The serum concentration of Metolazone can be increased when it is combined with Pipecuronium.
Pirbuterol
Pirbuterol may increase the hypokalemic activities of Metolazone.
Pirenzepine
The serum concentration of Metolazone can be increased when it is combined with Pirenzepine.
Pirfenidone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Pirfenidone.
Pirinitramide
The risk or severity of adverse effects can be increased when Piritramide is combined with Metolazone.
Piroxicam
The therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.
Piroxicam-Beta-Cyclodextrin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Piroxicam.
Polythiazide
Metolazone may increase the hypotensive activities of Polythiazide.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Metolazone.
Pramlintide
The therapeutic efficacy of Pramlintide can be decreased when used in combination with Metolazone.
Prasterone
Prasterone may increase the hypokalemic activities of Metolazone.
Prazosin
Prazosin may increase the hypotensive activities of Metolazone.
Prednicarbate
Prednicarbate may increase the hypokalemic activities of Metolazone.
Prednisolone
Prednisolone may increase the hypokalemic activities of Metolazone.
Prednisone
Prednisone may increase the hypokalemic activities of Metolazone.
Pregnenolone
Pregnenolone may increase the hypokalemic activities of Metolazone.
Primidone
Primidone may increase the orthostatic hypotensive activities of Metolazone.
Procaine
Procaine may increase the hypotensive activities of Metolazone.
Procarbazine
Procarbazine may increase the hypotensive activities of Metolazone.
Procaterol
Procaterol may increase the hypokalemic activities of Metolazone.
Procyclidine
The serum concentration of Metolazone can be increased when it is combined with Procyclidine.
Profenamine
The serum concentration of Metolazone can be increased when it is combined with Ethopropazine.
Propantheline
The serum concentration of Metolazone can be increased when it is combined with Propantheline.
Propantheline Bromide
The serum concentration of Metolazone can be increased when it is combined with Propantheline.
Propiverine
The serum concentration of Metolazone can be increased when it is combined with Propiverine.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Metolazone.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metolazone.
Propranolol
Metolazone may increase the hypotensive activities of Propranolol.
Proscillaridin
The risk or severity of adverse effects can be increased when Metolazone is combined with Proscillaridin.
Quetiapine
The risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Metolazone is combined with Quetiapine.
Quinapril
The risk or severity of hypotension can be increased when Metolazone is combined with Quinapril.
Quinidine
The serum concentration of Metolazone can be increased when it is combined with Quinidine.
Quinine
Quinine may increase the hypotensive activities of Metolazone.
Racepinephrine
Racepinephrine may increase the hypokalemic activities of Metolazone.
Ramipril
The risk or severity of hypotension can be increased when Metolazone is combined with Ramipril.
Rasagiline
Rasagiline may increase the hypotensive activities of Metolazone.
Regular Insulin, Human
The therapeutic efficacy of Insulin Human can be decreased when used in combination with Metolazone.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone.
Repaglinide
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Metolazone.
Rescinnamine
The risk or severity of hypotension can be increased when Metolazone is combined with Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Metolazone.
Resveratrol
The therapeutic efficacy of Metolazone can be decreased when used in combination with Resveratrol.
Rilmenidine
Rilmenidine may increase the hypotensive activities of Metolazone.
Rimexolone
Rimexolone may increase the hypokalemic activities of Metolazone.
Riociguat
Metolazone may increase the hypotensive activities of Riociguat.
Risperidone
Metolazone may increase the hypotensive activities of Risperidone.
Ritodrine
Ritodrine may increase the hypokalemic activities of Metolazone.
Rituximab
Metolazone may increase the hypotensive activities of Rituximab.
Rofecoxib
The therapeutic efficacy of Metolazone can be decreased when used in combination with Rofecoxib.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Metolazone.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Metolazone.
Rosiglitazone
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Metolazone.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Metolazone.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Metolazone.
Salicylamide
The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylamide.
Salicylic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Salicylic acid.
Salmeterol
Salmeterol may increase the hypokalemic activities of Metolazone.
Salsalate
The therapeutic efficacy of Metolazone can be decreased when used in combination with Salsalate.
Saxagliptin
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Metolazone.
Saxagliptin Anhydrous
The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Metolazone.
Scopolamine
The serum concentration of Metolazone can be increased when it is combined with Scopolamine.
Scopolamine Hydrobromide
The serum concentration of Metolazone can be increased when it is combined with Scopolamine.
Secobarbital
Secobarbital may increase the orthostatic hypotensive activities of Metolazone.
Selegiline
Selegiline may increase the hypotensive activities of Metolazone.
Selexipag
Metolazone may increase the hypotensive activities of Selexipag.
Serratiopeptidase
The therapeutic efficacy of Metolazone can be decreased when used in combination with Serrapeptase.
Sertraline
Sertraline may increase the hyponatremic activities of Metolazone.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Metolazone.
Sildenafil
Sildenafil may increase the antihypertensive activities of Metolazone.
Sitagliptin
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone.
Sitagliptin Phosphate
The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Metolazone.
Sodium Phosphate
Metolazone may increase the nephrotoxic activities of Sodium phosphate.
Sodium Phosphate, Monobasic
Metolazone may increase the nephrotoxic activities of Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Metolazone may increase the nephrotoxic activities of Sodium phosphate.
Solifenacin
The serum concentration of Metolazone can be increased when it is combined with Solifenacin.
Sotalol
The risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.
Spirapril
The risk or severity of hypotension can be increased when Metolazone is combined with Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Metolazone.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.
Sulfasalazine
The therapeutic efficacy of Metolazone can be decreased when used in combination with Sulfasalazine.
Sulpiride
The risk or severity of adverse effects can be increased when Metolazone is combined with Sulpiride.
Suprofen
The therapeutic efficacy of Metolazone can be decreased when used in combination with Suprofen.
Tacalcitol
The risk or severity of hyperkalemia can be increased when Tacalcitol is combined with Metolazone.
Tadalafil
Tadalafil may increase the antihypertensive activities of Metolazone.
Talinolol
Metolazone may increase the hypotensive activities of Talinolol.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Metolazone.
Tapentadol
The risk or severity of adverse effects can be increased when Tapentadol is combined with Metolazone.
Telmisartan
Metolazone may increase the hypotensive activities of Telmisartan.
Tenoxicam
The therapeutic efficacy of Metolazone can be decreased when used in combination with Tenoxicam.
Terazosin
The risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin.
Terbutaline
Terbutaline may increase the hypokalemic activities of Metolazone.
Terbutaline Sulfate
Terbutaline may increase the hypokalemic activities of Metolazone.
Teriflunomide
The therapeutic efficacy of Metolazone can be decreased when used in combination with Teriflunomide.
Terlipressin
Metolazone may increase the hypotensive activities of Terlipressin.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Metolazone.
Theodrenaline
Metolazone may increase the hypotensive activities of Theodrenaline.
Theophylline
Theophylline may increase the antihypertensive activities of Metolazone.
Theophylline anhydrous
Theophylline may increase the antihypertensive activities of Metolazone.
Thiamylal
Thiamylal may increase the orthostatic hypotensive activities of Metolazone.
Thiopental
Thiopental may increase the orthostatic hypotensive activities of Metolazone.
Thiopental Sodium
Thiopental may increase the orthostatic hypotensive activities of Metolazone.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Metolazone.
Tiaprofenic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Tiaprofenic acid.
Tibolone
Metolazone may increase the hypotensive activities of Tibolone.
Timolol
Timolol may increase the hypotensive activities of Metolazone.
Timolol Anhydrous
Timolol may increase the hypotensive activities of Metolazone.
Tiotropium
The serum concentration of Metolazone can be increased when it is combined with Tiotropium.
Tixocortol
Tixocortol may increase the hypokalemic activities of Metolazone.
Tizanidine
The risk or severity of adverse effects can be increased when Metolazone is combined with Tizanidine.
Tolazamide
The therapeutic efficacy of Tolazamide can be decreased when used in combination with Metolazone.
Tolazoline
Metolazone may increase the hypotensive activities of Tolazoline.
Tolbutamide
The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Metolazone.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Metolazone.
Tolfenamic Acid
The therapeutic efficacy of Metolazone can be decreased when used in combination with Tolfenamic Acid.
Tolmetin
The therapeutic efficacy of Metolazone can be decreased when used in combination with Tolmetin.
Toloxatone
Toloxatone may increase the hypotensive activities of Metolazone.
Tolterodine
The serum concentration of Metolazone can be increased when it is combined with Tolterodine.
Toremifene
Metolazone may increase the hypercalcemic activities of Toremifene.
Torsemide
Torasemide may increase the hypotensive activities of Metolazone.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Metolazone.
Trandolapril
The risk or severity of hypotension can be increased when Metolazone is combined with Trandolapril.
Tranilast
The therapeutic efficacy of Metolazone can be decreased when used in combination with Tranilast.
Tranylcypromine
Tranylcypromine may increase the hypotensive activities of Metolazone.
Travoprost
Travoprost may increase the hypotensive activities of Metolazone.
Treprostinil
Treprostinil may increase the hypotensive activities of Metolazone.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Metolazone.
Triamcinolone
Triamcinolone may increase the hypokalemic activities of Metolazone.
Triamterene
The risk or severity of adverse effects can be increased when Triamterene is combined with Metolazone.
Tribenoside
The therapeutic efficacy of Metolazone can be decreased when used in combination with Tribenoside.
Tricalcium Phosphate
Metolazone may decrease the excretion rate of Calcium Phosphate which could result in a higher serum level.
Trichlormethiazide
Metolazone may increase the hypotensive activities of Trichlormethiazide.
Trihexyphenidyl
The serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl.
Trihexyphenidyl Hydrochloride
The serum concentration of Metolazone can be increased when it is combined with Trihexyphenidyl.
Trimethaphan
The serum concentration of Metolazone can be increased when it is combined with Trimethaphan.
Troglitazone
The therapeutic efficacy of Troglitazone can be decreased when used in combination with Metolazone.
Tropicamide
The serum concentration of Metolazone can be increased when it is combined with Tropicamide.
Trospium
The serum concentration of Metolazone can be increased when it is combined with Trospium.
Tubocurarine
The serum concentration of Metolazone can be increased when it is combined with Tubocurarine.
Umeclidinium
The serum concentration of Metolazone can be increased when it is combined with Umeclidinium.
UNOPROSTONE
Metolazone may increase the hypotensive activities of Unoprostone.
Urapidil
Urapidil may increase the hypotensive activities of Metolazone.
Valdecoxib
The therapeutic efficacy of Metolazone can be decreased when used in combination with Valdecoxib.
Valsartan
Valsartan may increase the hypotensive activities of Metolazone.
Vardenafil
Vardenafil may increase the antihypertensive activities of Metolazone.
Vecuronium
The serum concentration of Metolazone can be increased when it is combined with Vecuronium.
Venlafaxine
Venlafaxine may increase the hyponatremic activities of Metolazone.
Verapamil
The risk or severity of adverse effects can be increased when Metolazone is combined with Verapamil.
Vilanterol
Vilanterol may increase the hypokalemic activities of Metolazone.
Vildagliptin
The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Metolazone.
Vincamine
Metolazone may increase the hypotensive activities of Vincamine.
Vinpocetine
Metolazone may increase the hypotensive activities of Vinpocetine.
Vitamin D
The risk or severity of hyperkalemia can be increased when Vitamin D is combined with Metolazone.
Xylometazoline
Metolazone may increase the hypotensive activities of Xylometazoline.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Metolazone.
Zileuton
The therapeutic efficacy of Metolazone can be decreased when used in combination with Zileuton.
Zofenopril
The risk or severity of hypotension can be increased when Metolazone is combined with Zofenopril.
Zomepirac
The therapeutic efficacy of Metolazone can be decreased when used in combination with Zomepirac.
